Carson Block, Muddy Waters Research
Carson Block, Muddy Waters Research
Carson Block is director of research and founding partner of Muddy Waters Research. Muddy Waters is a due diligence-based investment and research firm that conducts extensive accounting and on-the-ground investigations of public companies. Bloomberg Markets Magazine named Mr. Block as one of the “50 Most Influential in Global Finance” in 2011. In 2012, Muddy Waters received the Financial Times Boldness in Business Award.
Muddy Waters gained fame following its research on Sino-Forest Corp., a China-based forestry company listed on the Toronto Stock Exchange. Shortly after Muddy Waters issued its report in June 2011, Sino-Forest lost nearly $6 billion in market capitalization, its auditor resigned, regulators halted its shares and charged former management with fraud. The company filed for bankruptcy and in June 2012, the Ontario Securities Commission filed formal fraud charges against Sino-Forest and its senior management for overstating its timber assets and misleading investigators. In total, Muddy Waters has issued 10 “strong sell” recommendations resulting more than $8 billion of downward market cap adjustments, four de-listings and at least six regulatory investigations into company managements.
Mr. Block appears frequently as a commentator on Bloomberg Television, CNBC and the BBC. He has written op-eds in the Wall Street Journal, Financial Times, and New York Times on various topics related to improving corporate governance and market transparency.
Prior to forming Muddy Waters, Mr. Block was an entrepreneur in China and worked as a lawyer in the Shanghai office of the U.S. law firm Jones Day. In 2007, he co-authored Doing Business in China for Dummies, a primer on doing business in China. He holds a B.S. in business from the University of Southern California and a J.D. from the Chicago-Kent College of Law, where he has also served as an adjunct professor.
Jim Chanos, Kynikos Associates LP
Jim Chanos, Kynikos Associates LP
Jim Chanos is the founder and Managing Partner of Kynikos Associates LP. As the world’s largest exclusive short selling investment firm, Kynikos Associates LP provides investment management services for domestic and offshore clients. Through investment funds, partnerships, corporations, and managed accounts – domestic and offshore – Kynikos Associates LP maintains private portfolios of securities for clients. The Ursus, Kriticos and Kynikos Opportunity funds seek to profit from the unusually high alphas found on the long and short side of the U.S. and non-U.S. equity markets.
Marc Chatin, Parus Finance
Marc Chatin, Parus Finance
Marc Chatin is a Partner at Parus Finance and a co-Portfolio Manager of the Parus Fund, a global long/short equity fund with a net annualized return of 17.3% since 2003. Investments are fundamentally based with a 3-5 year view, with a focus on growth companies with a competitive advantage on the long side and structurally declining companies on the short side. Alongside these investments, the Fund also takes positions in companies with cyclical, mean reverting characteristics. The Fund does not use leverage and has a variable net exposure through the equity market cycle.
Marc is one of the four portfolio managers and is involved in all aspects of the investment process. Marc has been investing in long/short equity since 2005 and has worked for several multi-billion dollar equity long short funds either as a generalist or as a portfolio manager focusing on TMT sectors. Marc also worked in corporate business development for Cisco, the technology company,and in M&A for Rothschild in Paris. Marc has an MBA from Wharton.
Mala Gaonkar, Lone Pine Capital
Mala Gaonkar, Lone Pine Capital
Mala Gaonkar is co-portfolio manager at investment firm Lone Pine Capital LLC, a role she has held since 1998. After graduating from Harvard in 1991, she worked for The Boston Consulting Group, primarily in Munich and Hong Kong, and completed her MBA at Harvard Business School before Lone Pine’s inception.
She is a trustee of the Clinton Health Access Initiative (CHAI), Ariadne Labs, The Harvard School of Public Health, and is a founding trustee of The Queen Elizabeth Prize for Technology. She also serves as a trustee of The Paris Review Foundation and of the Tate.
Ali Hedayat, Indus Capital
Ali Hedayat, Indus Capital
Ali Hedayat is a partner at Indus Capital and the co-CIO of the Indus Markor fund, a concentrated special situations vehicle focussed on overlooked opportunities globally.
Ali started his career at Goldman Sachs in 1997 as a sell side analyst, covering a number of industries in Latin America. He joined the Risk Arbitrage/Principal Strategies group in 1999, driving the development of the business both in Europe and across the non-Asian emerging markets. From 2007-2010, Ali was the co-head of Goldman’s Americas Principal Strategies Business, successfully leading it through one of the more turbulent periods in its history. Ali left Goldman in 2010 to start Edoma with a number of former colleagues and joined Indus in 2013.
Ali sits on corporate boards in the pharmaceutical and entertainment industries as well as on charitable boards focussed on Persian cultural and community causes. He holds a BComm with honours from McGill university and lives in London with his wife and two daughters.
Mans Larsson, Makuria Investment Management
Mans Larsson, Makuria Investment Management
Måns Larsson founded Makuria Investment Management, a European value fund, in April 2013. Makuria invests long and short across the capital structure in debt and equity driven by fundamental bottom-up analysis. Prior to establishing Makuria, Mr Larsson was the head of Canyon Capital’s London office. Mr. Larsson was responsible for Canyon’s European portfolio and focused primarily on European credit and distressed investment opportunities. Prior to joining Canyon in 2007, Mr. Larsson worked at Silver Point in London where he invested in distressed and special situation securities across the capital structure. Prior to that, Mr. Larsson invested in European private equity at Altor Equity Partners and Hicks, Muse, Tate & Furst. Mr. Larsson started his career in the private equity group at Goldman, Sachs & Co. Mr. Larsson graduated from Harvard University (B.A., magna cum laude) and Harvard Business School (M.B.A.).
Marc Lasry, Avenue Capital Group
Marc Lasry, Avenue Capital Group
Marc Lasry is the Chairman, Chief Executive Officer and Co-Founder of Avenue Capital Group, a global alternative investment manager focused on distressed and undervalued debt and equity opportunities in the U.S., Europe and Asia. In 1995, Mr. Lasry formed Avenue with his sister Sonia Gardner with less than $10 million in capital from friends and family. Today, Avenue is one of the largest distressed debt investors globally, managing assets of approximately $14.1 billion, with headquarters in New York City, and offices in London, Luxembourg, Munich, Madrid, and four offices throughout Asia.
Mr. Lasry is known as a pioneer in distressed investing which has been the focus of his professional career for over 30 years.
After law school, Mr. Lasry clerked for Edward Ryan, Chief Bankruptcy Judge for the Southern District of New York. He spent the following year practicing law at Angel & Frankel, which focused on bankruptcies. Mr. Lasry subsequently became the Director of the private debt department at R.D. Smith, the firm where he first became involved in “trade claims,” the market in purchasing and selling to investors the unsecured claims of vendors and other creditors against a debtor. In 1987, he moved to Cowen & Company where he was Co-Director of the bankruptcy and corporate reorganization department. It was at Cowen that he caught the attention of the Texas investor Robert Bass, who was a client of the firm. When he left Cowen, Mr. Lasry went to manage over $100 million for the Robert Bass Group, Inc., where he invested in bank debt, senior bonds, and trade claims. The Bass fund Mr. Lasry oversaw was called Amroc Investments, L.P., and, at the time, it stood as one of the largest distressed funds in the U.S. In 1990, he co-founded a boutique distressed keeping the Amroc name and maintaining the affiliation with the Robert Bass Group.
Mr. Lasry serves as a member of the Board of Trustees of The Mount Sinai School of Medicine and as a member of the Board of Directors of both The Clinton Global Initiative and the 92nd Street YMHA. Mr. Lasry received a B.A. in History from Clark University (1981) and a J.D. from New York Law School (1984).
Yaser Martini, Team Margot
Yaser Martini, Team Margot
Yaser qualified as a chartered surveyor in 1994 and was previously at leisure and hospitality property specialists, Fleurets for 18 years. He has since worked in the ultra high end residential property market, co-founded Miso Tasty Ltd and is a non-executive board member at Beds and Bars Group (backpacker hostels), Cirrus Inns (pub company), PubAid, Portman Square Holdings and Instinctive PR. He is married and father to three children, including Margot. Team Margot is Margot’s family & friends of the family who together raised awareness of Margot’s plight and that of others like her desperately seeking a blood stem cell donor match.
Team Margot launched Margot’s donor appeal on Christmas Eve 2013 and are credited as having run the most high profile global donor appeal anywhere in the world, embracing national and international TV, radio, print, online, outdoor media and Virgin America flights. Within the first 6 weeks of launch the charity, Delete Blood Cancer UK received over 50,000 requests for swab kits in the UK alone.
As a result of Team Margot’s efforts to date, statistically there will be over 500 people who will now have the option of a donor match that could potentially save their life.
Team Margot is committed to raising awareness around the need for more stem cell donor recruits and in particular more recruits with a mixed genealogy. Margot’s mixed family background was the key difficulty in finding her a perfect match.
Michael Messara, Caledonia
Michael Messara, Caledonia
Michael Messara is the Senior Portfolio Manager and an Executive Director of Caledonia, a $2.6 billion long short global equity management firm. Caledonia employs a long term, fundamental research and theme-based approach to its investments, taking concentrated positions in high conviction opportunities. Founded in 1992, Caledonia has offices in Sydney and New York.
Michael joined Caledonia in 2006 after spending five years with UBS AG in Sydney. While at UBS, Michael held a number of roles in equity research with a particular emphasis on the materials, healthcare, media, gaming and small-caps sectors. Immediately prior to joining Caledonia, Michael was leading a top-rated team of UBS analysts covering small- to mid-cap Australian companies.
Michael holds a Bachelor of Commerce from Bond University. He is a Non-Executive director of GraysOnline and Arrowfield Pastoral Company.
Prof. Christopher Nutting, The Royal Marsden Hospital
Prof. Christopher Nutting, The Royal Marsden Hospital
Professor Nutting is head of the Division of Radiotherapy and Imaging at the Institute of Cancer Research and Royal Marsden Hospital. He specializes in developing and testing new cancer treatments which integrate state of the art technology into radiotherapy. The goals of the research developments are to increase cancer control rates and minimize side effects of treatment.
Richard S. Pzena, Pzena Investment Management
Richard S. Pzena, Pzena Investment Management
Richard S. Pzena is the Founder, and Co-Chief Investment Officer of Pzena Investment Management. Pzena Investment Management is a global investment management firm that employs a classic value investment approach. The firm began managing assets on January 1, 1996 and has grown to manage approximately $27.0 billion (as of June 2014) for clients around the world. Rich is the architect of the firm’s investment strategy, conceived and developed our proprietary screening model and serves as co-portfolio manager on each of the firm’s US investment strategies. Prior to forming Pzena Investment Management, Mr. Pzena was the Director of U.S. Equity Investments and Chief Research Officer for Sanford C. Bernstein & Company. He joined Bernstein in 1986 as an oil industry analyst and was named to the Institutional Investor All America Research Team from 1988-1990. Prior to joining Bernstein, Mr. Pzena worked for the Amoco Corporation in various financial and planning roles. He earned a B.S. summa cum laude and an MBA from the Wharton School of the University of Pennsylvania in 1979 and 1980 respectively.
Guillaume Rambourg, Verrazzano Capital
Guillaume Rambourg, Verrazzano Capital
Guillaume Rambourg, prior to joining Verrazzano Capital as a Founding Partner, Guillaume was co-portfolio manager of the AlphaGen Capella, AlphaGen Tucana and AlphaGen Acamar hedge funds at Gartmore Investment Management where he co-ran $5 billion in assets under management (AUM) at the peak across both strategies (peaked in 2008 and again in 2009). Guillaume joined Gartmore in 1995 as an analyst and was co-manager from inception of both the AlphaGen Capella hedge fund (1999-2010) and AlphaGen Tucana (2005-10). In addition, Guillaume co-managed European long-only mandates, including Gartmore European Selected Opportunities Fund and Gartmore SICAV Continental European Fund, totaling AUM $8 billion at the peak. Guillaume graduated from ESSEC Business School in Paris (1993), majoring in Finance. The funds he co-managed were the recipients on various occasions of awards from Eurohedge for Best European Long Short Fund (Over $500m category): AlphaGen Capella 2001, AlphaGen Tucana 2006, AlphaGen Tucana 2009.
Bruno Rocha, Dynamo
Bruno Rocha, Dynamo
Bruno Rocha co-founded Dynamo in Brazil in 1993. Until 2006, the firm was exclusively dedicated to investing in Brazilian equities and Bruno was responsible for managing the portfolio. He then moved to London to set up an international fund mainly focused in European equities.
Dinakar Singh, TPG-Axon Capital
Dinakar Singh, TPG-Axon Capital
Dinakar Singh is the founding partner of TPG- Axon Capital, a leading global investment firm. Through offices in New York, London, Hong Kong and Tokyo, TPG-Axon invests across global markets and asset classes. The firm was founded by Mr. Singh in late 2004, in partnership with Texas Pacific Group.
He was previously a partner at Goldman Sachs, where he was co-head of the Principal Strategies department. During his 14 years at Goldman Sachs, he served on a number of the firm’s key leadership committees, including the Securities Division Operating Committee, Risk Committee, Partnership Committee, and Asia Management Committee.
He serves on the Yale University Investment Committee and the Boards of the New York Public Library, Columbia University Medical Center, The Rockefeller University and Cold Spring Harbor Laboratories.
Nicolai Tangen, AKO Capital
Nicolai Tangen, AKO Capital
Nicolai Tangen is the founder and CEO of AKO Capital, a $9 billion European equity manager. Before setting up AKO Capital, Tangen was a partner at Egerton Capital where he was voted Best Individual European Small Cap Fund Manager by finance directors in the Reuters Survey in both 1999 and in 2001. Prior to joining Egerton, Tangen worked as an equity analyst at Cazenove & Co., where he built up and headed the Nordic department.
Leah Zell, Lizard Investors